{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:09:24Z","timestamp":1778602164048,"version":"3.51.4"},"reference-count":35,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014072","name":"Amsterdam University Fund","doi-asserted-by":"crossref","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/501100014072","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bekker-la Bastide-Fonds","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]},{"name":"Fund Girn","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurologic Disorders and Stroke","doi-asserted-by":"crossref","award":["U01NS082329"],"award-info":[{"award-number":["U01NS082329"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["RG 4778-A-6"],"award-info":[{"award-number":["RG 4778-A-6"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018229","name":"Jo Kolk Studiefonds","doi-asserted-by":"crossref","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}],"id":[{"id":"10.13039\/100018229","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Dutch MS Research Foundation","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]},{"name":"MediciNova","award":["Not Applicable"],"award-info":[{"award-number":["Not Applicable"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2025,12,8]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple sclerosis (MS) involves cortical injury, including cortical lesion (CL) development. Ibudilast treatment was found to slow progression of whole brain and cortical atrophy, but the effect of ibudilast on CLs is unknown. The present study aims to evaluate the treatment effect of ibudilast on CL development and whether the effect of ibudilast on brain atrophy is modified by CLs in primary-progressive MS (PPMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this longitudinal study, we analysed data of 102 people with PPMS (ibudilast: n=49; placebo: n=53) from the Secondary and Primary Progressive Ibudilast NeuroNEXT Trial in Multiple Sclerosis. CLs were identified on artificial intelligence-generated double inversion-recovery images created from T1 and T2 images at 3T MRI and rated at baseline and week 96. Atrophy was measured by cortical thickness and brain parenchymal fraction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CLs were detected in all participants with PPMS with a median count of 22 (11\u201334) in the ibudilast group and 28 (13\u201344) in the placebo group. At baseline, treatment groups did not differ in any brain volume measure or CL count. Higher CL counts at baseline were associated with higher CL formation during follow-up (\n                      <jats:italic>B(95%\u2009CI<\/jats:italic>\n                      )=0.20 (0.12 to 0.29), p&lt;0.001), independent of ibudilast treatment.\n                    <\/jats:p>\n                    <jats:p>\n                      Change in CL count did not differ between treatment groups (\n                      <jats:italic>mean difference<\/jats:italic>\n                      (\n                      <jats:italic>SD<\/jats:italic>\n                      )=0.07 (0.29), p=0.364). Protective effect of ibudilast on cortical thickness was more prominent in subjects with greater CL formation, but this relationship was not observed with whole brain atrophy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ibudilast treatment does not affect CL development in PPMS. Its protective effect on cortical thinning is more prominent with greater CL formation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01982942\">NCT01982942<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2025-001335","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:15:10Z","timestamp":1767687310000},"page":"e001335","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of cortical pathology in primary-progressive multiple sclerosis: a post hoc analysis of the SPRINT-MS trial"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct01982942","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01982942","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3628-4127","authenticated-orcid":false,"given":"Eva A","family":"Krijnen","sequence":"first","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Anatomy and Neurosciences, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M","family":"Bruijn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ani","family":"Eloyan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Brown University, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2504-6959","authenticated-orcid":false,"given":"Menno M","family":"Schoonheim","sequence":"additional","affiliation":[{"name":"Anatomy and Neurosciences, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J","family":"Fox","sequence":"additional","affiliation":[{"name":"Neurology, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric C","family":"Klawiter","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"2026051208150932000_8.1.e001335.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.26858"},{"key":"2026051208150932000_8.1.e001335.2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25145"},{"key":"2026051208150932000_8.1.e001335.3","doi-asserted-by":"crossref","DOI":"10.1002\/wsbm.1583","article-title":"Neurodegeneration in multiple sclerosis","volume":"15","author":"Mey","year":"2023","journal-title":"WIREs Mech Dis"},{"key":"2026051208150932000_8.1.e001335.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0035-2"},{"key":"2026051208150932000_8.1.e001335.5","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11123342","article-title":"Novel Drugs in a Pipeline for Progressive Multiple Sclerosis","volume":"11","author":"Sapko","year":"2022","journal-title":"J Clin Med"},{"key":"2026051208150932000_8.1.e001335.6","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27238448","article-title":"Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast for Neurodegenerative Diseases: An Update on Preclinical and Clinical Evidence","volume":"27","author":"Angelopoulou","year":"2022","journal-title":"Molecules"},{"key":"2026051208150932000_8.1.e001335.7","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1212\/WNL.0b013e3181d7d651","article-title":"Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?","volume":"74","author":"Barkhof","year":"2010","journal-title":"Neurology (ECronicon)"},{"key":"2026051208150932000_8.1.e001335.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803583"},{"key":"2026051208150932000_8.1.e001335.9","first-page":"e491","article-title":"Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study","volume":"96","author":"Naismith","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2026051208150932000_8.1.e001335.10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/acn3.51251","article-title":"Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype","volume":"8","author":"Goodman","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"2026051208150932000_8.1.e001335.11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/13524585231224702","article-title":"Ibudilast reduces slowly enlarging lesions in progressive multiple sclerosis","volume":"30","author":"Nakamura","year":"2024","journal-title":"Mult Scler"},{"key":"2026051208150932000_8.1.e001335.12","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1001\/jamaneurol.2015.1241","article-title":"Association of Cortical Lesion Burden on 7-T Magnetic Resonance Imaging With Cognition and Disability in Multiple Sclerosis","volume":"72","author":"Harrison","year":"2015","journal-title":"JAMA Neurol"},{"key":"2026051208150932000_8.1.e001335.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10400-4"},{"key":"2026051208150932000_8.1.e001335.14","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.0b013e3181a0fee5","article-title":"Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study","volume":"72","author":"Calabrese","year":"2009","journal-title":"Neurology (ECronicon)"},{"key":"2026051208150932000_8.1.e001335.15","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21906"},{"key":"2026051208150932000_8.1.e001335.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70191-1"},{"key":"2026051208150932000_8.1.e001335.17","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2010.93"},{"key":"2026051208150932000_8.1.e001335.18","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511406575"},{"key":"2026051208150932000_8.1.e001335.19","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2361040450"},{"key":"2026051208150932000_8.1.e001335.20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/13524585211029860","article-title":"Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis","volume":"28","author":"Bouman","year":"2022","journal-title":"Mult Scler"},{"key":"2026051208150932000_8.1.e001335.21","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.221425","article-title":"Multicenter Evaluation of AI-generated DIR and PSIR for Cortical and Juxtacortical Multiple Sclerosis Lesion Detection","volume":"307","author":"Bouman","year":"2023","journal-title":"Radiology"},{"key":"2026051208150932000_8.1.e001335.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2016.08.009"},{"key":"2026051208150932000_8.1.e001335.23","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213650","article-title":"Evolution of Cortical Lesions and Function-Specific Cognitive Decline in People With Multiple Sclerosis","volume":"104","author":"Krijnen","year":"2025","journal-title":"Neurology (ECronicon)"},{"key":"2026051208150932000_8.1.e001335.24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1212\/WNL.0b013e31820a0cc4","article-title":"Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI","volume":"76","author":"Geurts","year":"2011","journal-title":"Neurology (ECronicon)"},{"key":"2026051208150932000_8.1.e001335.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mri.2012.05.001"},{"key":"2026051208150932000_8.1.e001335.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2010.07.052"},{"key":"2026051208150932000_8.1.e001335.27","doi-asserted-by":"crossref","unstructured":"Fisher E , Cothren RM , Tkach JA , et al . knowledge-based 3D segmentation of the brain in MR images for quantitative multiple sclerosis lesion tracking. SPIE; 1997:19\u201325. doi:10.1117\/12.274117","DOI":"10.1117\/12.274117"},{"key":"2026051208150932000_8.1.e001335.28","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1093\/brain\/aws246","article-title":"Cortical lesion load associates with progression of disability in multiple sclerosis","volume":"135","author":"Calabrese","year":"2012","journal-title":"Brain (Bacau)"},{"key":"2026051208150932000_8.1.e001335.29","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.1.76"},{"key":"2026051208150932000_8.1.e001335.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100648"},{"key":"2026051208150932000_8.1.e001335.31","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/brain\/aww037","article-title":"Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study","volume":"139","author":"Kilsdonk","year":"2016","journal-title":"Brain (Bacau)"},{"key":"2026051208150932000_8.1.e001335.32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/acn3.52261","article-title":"Cortical lesions impact cognitive decline in multiple sclerosis via volume loss of nonlesional cortex","volume":"12","author":"Krijnen","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"2026051208150932000_8.1.e001335.33","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.nicl.2016.05.017","article-title":"A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer\u2019s disease severity","volume":"11","author":"Schwarz","year":"2016","journal-title":"Neuroimage Clin"},{"key":"2026051208150932000_8.1.e001335.34","doi-asserted-by":"crossref","DOI":"10.1186\/s13317-019-0117-5","article-title":"Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options","volume":"10","author":"Andravizou","year":"2019","journal-title":"Auto Immun Highlights"},{"key":"2026051208150932000_8.1.e001335.35","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A5534"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:15:30Z","timestamp":1778598930000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,5]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjno-2025-001335"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001335","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}